Alphamab Oncology reports stable share capital in August

Alphamab Oncology (HKEX:9966) reported a steady state in its share capital for the month ended August 31, 2025, with no new shares issued or repurchased. The total number of authorized/registered shares remained at 25.1bn ordinary shares, with a par value of $0.000002 per share, totaling $50,200 in authorized/registered share capital.

The company's issued share capital also held firm, with 971,195,697 ordinary shares (excluding treasury shares) and 2,952,000 treasury shares, resulting in a total of 974,147,697 issued shares. No movements were recorded in share options during the month.

The company’s Scheme Mandate Limit was refreshed to 96,492,380 ordinary shares on June 12, 2024, following shareholder approval. This limit represents 10% of the company's issued shares as of the approval date. The refreshment, which took effect on July 16, 2024, includes 95,433,772 ordinary shares for issuance and 1,058,608 ordinary shares from a lapsed Restricted Share Award Scheme.